Danish drugmaker Novo Nordisk is in a buy range after breaking out of a cup base and passing its 117.45 buy point. The company produces drugs to combat diabetes, hormone disorders and obesity. The FDA approved Novo Nordisk's drug Ozempic for treatment of type 2 diabetes on March 28.
Via:: Sports Headlines
